lamivudine and zidovudine tablet, film coated
aurobindo pharma limited - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - lamivudine 150 mg - lamivudine and zidovudine tablets, a combination of 2 nucleoside analogues, are indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. lamivudine and zidovudine tablets are contraindicated in patients with a previous hypersensitivity reaction to lamivudine or zidovudine. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lamivudine and zidovudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for lamivudine or zidovudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses the macdp as the u.s. reference population for birth defe
lamivudine 150mg and zidovudine tablets 300 mg film-coated tablet
lamivudine usp, zidovudine usp - film-coated tablet - lamivudine usp 150mg, zidovudine usp 150mg - zidovudine and lamivudine
abacavir, lamivudine and zidovudine- abacavir , lamivudine and zidovudine tablet
lupin pharmaceuticals, inc. - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s), abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - lamivudine 150 mg - abacavir, lamivudine and zidovudine tablet is indicated in combination with other antiretrovirals or alone for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. limitations of use: - limited data exist on the use of abacavir, lamivudine and zidovudine tablets alone in patients with higher baseline viral load levels (greater than 100,000 copies per ml) [see clinical studies (14)] . abacavir, lamivudine and zidovudine tablets are contraindicated in patients: - who have the hla-b*5701 allele [see warnings and precautions (5.1)]. - with prior hypersensitivity reaction to abacavir [see warnings and precautions (5.1)], lamivudine, or zidovudine. - with moderate or severe hepatic impairment [see use in specific populations (8.7)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir, lamivudine and zidovudine tablets during pregnancy. healthcare providers are encouraged to register patients
abacavir sulfate, lamivudine and zidovudine tablet
lupin limited - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s), abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - lamivudine 150 mg - abacavir, lamivudine and zidovudine tablet is indicated in combination with other antiretrovirals or alone for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. limitations of use: - limited data exist on the use of abacavir, lamivudine and zidovudine tablets alone in patients with higher baseline viral load levels (greater than 100,000 copies per ml) [see clinical studies (14)] . abacavir, lamivudine and zidovudine tablets are contraindicated in patients: - who have the hla-b*5701 allele [see warnings and precautions (5.1)]. - with prior hypersensitivity reaction to abacavir [see warnings and precautions (5.1)], lamivudine, or zidovudine. - with moderate or severe hepatic impairment [see use in specific populations (8.7)] . teratogenic effects pregnancy category c: there are no adequate and well-controlled studies of abacavir, lamivudine and zidovudine tablets in pregnant women. reproduction studies with abacavir, lamivudine, and zidovudine have been p
zidovudine syrup
cipla ltd. - zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - zidovudine 50 mg in 5 ml - zidovudine syrup (zidovudine oral solution), a nucleoside reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. zidovudine syrup (zidovudine oral solution) is indicated for the prevention of maternal-fetal hiv-1 transmission [see dosage and administration (2.3)] . the indication is based on a dosing regimen that included 3 components: - antepartum therapy of hiv-1 infected mothers - intrapartum therapy of hiv-1 infected mothers - post-partum therapy of hiv-1 exposed neonate. points to consider prior to initiating zidovudine in pregnant women for the prevention of maternal-fetal hiv-1 transmission include: - in most cases, zidovudine for prevention of maternal-fetal hiv-1 transmission should be given in combination with other antiretroviral drugs. - prevention of hiv-1 transmission in women who have received zidovudine for a prolonged period before pregnancy has not been evaluated. - because the fetus is most susceptible to
lamivudine & zidovudine inovamed 150 mg300 mg
inovamed ltd - lamivudine; zidovudine - film coated tablets - lamivudine 150 mg; zidovudine 300 mg - zidovudine - lamivudine & zidovudine inovamed 150 mg / 300 mg is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection.
arrow lz (lamivudine 150mg and zidovudine 300mg ) tablets
unimed sdn bhd - lamivudine; zidovudine -
lamivudine + zidovudine alphapharm
alphapharm pty ltd - zidovudine; lamivudine -
lamivudine/zidovudine viatris 150/300
viatris limited - lamivudine 150mg; zidovudine 300mg - film coated tablet - active: lamivudine 150mg zidovudine 300mg excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose opadry white propylene glycol purified water sodium starch glycolate - indicated for the treatment of hiv infected adults and adolescents over the age of 12 years, with progressive immunodeficiency (cd4+ count = < 500 cells/mm³).
teva-lamivudine/zidovudine tablet
teva canada limited - lamivudine; zidovudine - tablet - 150mg; 300mg - lamivudine 150mg; zidovudine 300mg - nucleoside and nucleotide reverse transcriptase inhibitors